17:15 , Apr 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Esophageal cancer; cancer Cell culture and mouse studies suggest SLC7A11 inhibitors could help treat p53 -mutant esophageal cancer and other cancers that are resistant to p53 activators. In 10 p53-mutant esophageal cancer cell lines,...
08:00 , Nov 7, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Solute carrier family 7 member 11 cystine glutamate transporter (SLC7A11; xCT) In vitro and mouse studies suggest xCT inhibitors could help treat a...
07:00 , Jul 1, 2013 |  BioCentury  |  Strategy

RAtcheting back

A study by the U.S. Department of Veterans Affairs could push Amgen Inc. 's Enbrel etanercept and other TNF alpha inhibitors back to third-line therapy for RA. More importantly, similar payer-backed studies testing cost-containment strategies...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

Enbrel etanercept: Data

Researchers at the Department of Veterans Affairs and colleagues reported data from the double-blind, U.S. and Canadian RACAT trial in 353 RA patients with active disease despite methotrexate therapy showing that initial therapy with once-weekly...
00:44 , Jun 13, 2013 |  BC Extra  |  Clinical News

VA researchers recommend delaying use of Enbrel for RA

Researchers at the Department of Veterans Affairs published a study that they said suggests a strategy of first administering a triple therapy of generics to treat adults with active rheumatoid arthritis (RA) before switching to...
08:00 , Feb 23, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL) Solute carrier family 7 member 11 cysteine glutamate transporter (SLC7A11; xCT) In vitro and mouse studies suggest the xCT inhibitor sulfasalazine...
07:00 , Sep 22, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Seizures Solute carrier family 7 member 11 cysteine glutamate transporter (SLC7A11; xCT) Mouse studies suggest the xCT blocker Azulfidine sulfasalazine could...
07:00 , Aug 31, 2009 |  BC Week In Review  |  Clinical News

PMI-001: Phase IIb data

A completer analysis of 62 patients from a double-blind, active-controlled, U.S. Phase IIb trial showed that 60 mg PMI-001 thrice daily met the primary endpoint of an ACR20 response at 6 months compared with 1g...
07:00 , Jun 29, 2009 |  BC Week In Review  |  Clinical News

Enbrel etanercept: Phase IV data

In a post-hoc analysis of 566 patients in the double-blind Phase IV ASCEND trial, patients who received 50 mg once-weekly Enbrel showed a significantly greater improvement in physical function (47.8% vs. 28.5%), spinal mobility (25%...
07:00 , May 29, 2008 |  BC Innovations  |  Targets & Mechanisms

Swell Effect on Glioma

Gliomas, unlike most other tumor types, grow and expand by killing off surrounding tissue, causing neurodegeneration and edema. Chemotherapy and radiotherapy attack the tumor itself, but do not address these two other effects of the...